Fraunhofer develops automated production technologies for mRNA-based drugs

Small glas bottle which is normally used to store vaccine

Fraunhofer develops automated production technologies for mRNA-based drugs

{post_date}  •  {terms}

2. June 2022  •  Cell / Gene technology

Coordinated by the Fraunhofer Institute for Cell Therapy and Immunology IZI, seven Fraunhofer institutes are working on the development of automated production technologies for mRNA-based drugs. RNAuto is a Fraunhofer lighthouse project that will receive €8 million in funding from the Fraunhofer-Gesellschaft over the next four years.

mRNA-based vaccines, along with gene and cell therapeutics, represent innovative drugs that can be used to prevent and/or treat infectious diseases, genetic disorders and cancer. Development of these innovative drugs has been prodigious in recent years in terms of clinical research, translation and application. But advancement of the required production technologies has not yet managed to keep pace with the rapid biomedical progress made in these areas. Hence the need for automated and digitally supported production technologies that facilitate not only the rapid, safe and reliable development of innovative mRNA drugs, but also their production in accordance with the high demands of good manufacturing practice (GMP).

This lighthouse project focuses on developing bioprocessing methods and production technologies for the modular and automated manufacture of mRNAs, mRNA nanocarriers and mRNA-modified cells that can be scaled right up to industry level. For the automated manufacture of mRNA-based drugs to be successful, technical solutions will be established in the areas of bioreactors, fluid dynamics, quality control and automated data analysis. Core elements of the Industry 4.0 concept are to be deployed in order to digitally map and monitor the production processes.

The primary objective is to develop automated manufacturing processes for mRNA molecules that will smooth the way for sustainable and cost-efficient health care. In order to achieve its goal, the project brings together the expertise of various Fraunhofer institutes from the fields of vaccine development, cell and gene therapy, bioprocess development, smart sensor technology, and the automation and digitalization of production processes.

Fraunhofer IZI is contributing its expertise in the development of innovative vaccine technologies and cell-based immune therapeutics. Besides developing GMP-compliant manufacturing processes, the project will also benefit from the institute’s competences in the fields of molecular drug design and preclinical testing of novel drug candidates.

Through its lighthouse projects, Fraunhofer addresses current challenges facing German industry and sets strategic focus areas that will aid the development of specific solutions across Germany. The RNAuto lighthouse project will be financed by the Fraunhofer-Gesellschaft until the end of 2025 with €8 million in funding.

More

First in Europe: All approved CAR-T cell therapy products are available at the University Hospital Leipzig (UKL).

Small glas bottle which is normally used to store vaccine

cell-immune-gene-therapies

Small glas bottle which is normally used to store vaccine

Chimeric Antigen Receptor T Cell Therapy (CAR-T): Genetically programmed immune cell binds to and destroys cancer cell / Therapy is now available for the majority of indications

Smart Infrastructure Hub in Leipzig receives a further 1,9 million euros in funding

Human who looks onto a recording of brainwaves on his tablet computer and moves the model with his fingers

digital-health

Human who looks onto a recording of brainwaves on his tablet computer and moves the model with his fingers

The Smart Infrastructure Hub Leipzig will receive a further 1,9 million euros from the cluster funding of the Saxon Ministry of Economic Affairs.

BIO-Europe 2022 in Leipzig/Saxony breaks records

Small glas bottle which is normally used to store vaccine

cell-immune-gene-therapies

Small glas bottle which is normally used to store vaccine

A relatively small metropolis in Germany’s Free State of Saxony – a dynamic hub for the life science industry? What was just a vision 20 years ago has become a reality for the city of Leipzig, which from October 24-26 co-hosted BIO-Europe, Europe’s largest annual biotech partnering event.

Back to top